Skip to main content
. 2021 Apr 19;36(4):766–772. doi: 10.1038/s41433-021-01538-6

Table 1.

Demographics, questionnaire scores and sex hormone serum levels of all AI patients included in the study. Classification of dry eye disease was based on OSDI score (i.e. ≥13).

Total Asymptomatic Symptomatic p
No. of patients, n (%) 25 9 (36) 16 (64)
Age, years (mean, SD) 62.3 ± 10 61.3 ± 9.3 62.8 ± 10.6 0.730
AI duration, months (mean, SD)a 35.8 ± 26.4 26.87 ± 19.4 40.78 ± 29.04 0.304
Breast cancer treatment, n (%)
  Radiotherapy 18 (72) 6 (67) 12 (75) 0.656
  Chemotherapy 24 (96) 7 (79) 12 (75) 0.876
  Breast surgery 20 (80) 8 (89) 15 (94) 0.667
  Biological therapy 4 (16) 2 (22) 2 (13) 0.524
BMI score 28.4 ± 10.8 27.45 ± 3.5 28.87 ± 13.36 0.759
BMI, n (%)
  Normal 10 (40) 2 (25) 8 (50) 0.394
  Overweight 13 (52) 6 (75) 7 (44)
  Obese 2 (8) 1 (13) 1 (6)
Waist circumference, cm (mean, SD) 80 ± 27 92.6 ± 11.6 72.7 ± 31.1 0.081
Questionnaires (mean, SD)
  OSDI 24.1 ± 18.1 6.2 ± 4.9 34.1 ± 14.6 <0.001
  SPEED 9 ± 6 5.7 ± 5.0 11.0 ± 4.9 0.015
  FACT-ES 147.9 ± 19.4 146.4 ± 18.9 148.7 ± 20.2 0.787
Serum levels (mean, SD)
  Cholesterol, mmol/L 5.3 ± 0.9 5.5 ± 0.7 5.1 ± 1.0 0.429
  Testosterone, nmol/L 0.6 ± 0.5 0.5 ± 0.1 0.7 ± 0.6 0.202
  DHEA, nmol/La 9.6 ± 6.6 7.7 ± 4.8 10.7 ± 7.3 0.698
  SHBG, nmol/L 66 ± 32.3 59.3 ± 19.6 69.4 ± 37.1 0.484
 Estradiol, pmol/L (n, %)b
   <5 21 (88) 7 (88) 14 (88) 0.999
   <10 2 (8) 1 (12) 1 (6)
   75 1 (4) 0 1 (6)

One patient did not follow up with blood collection.

Key: AI Aromatase inhibitor, SD Standard deviation, BMI Body mass index, OSDI Ocular surface disease index, SPEED Standard patient evaluation of eye dryness, FACT-ES Functional Assessment of Cancer Therapy: For patients with Endocrine symptoms, mmol/L millimoles per litre, nmol/L nanomoles per litre, pmol/L picomoles per litre.

aMann–Whitney U test.

bFisher Exact Test.

Bold values shown significant difference i.e. p < 0.05.